Nephros, Inc. (NEPH)
USD 1.48
(-3.9%)
USD 1.48
(-3.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.37 Million USD | 65.86% |
| 2022 | -3.9 Million USD | 1.63% |
| 2021 | -2.23 Million USD | 7.46% |
| 2020 | -3.93 Million USD | -40.19% |
| 2019 | -3 Million USD | -9.74% |
| 2018 | -3.08 Million USD | -43.91% |
| 2017 | -2.07 Million USD | 23.92% |
| 2016 | -2.63 Million USD | 17.92% |
| 2015 | -2.83 Million USD | -30.87% |
| 2014 | -6.67 Million USD | 26.83% |
| 2013 | -3.35 Million USD | -5.38% |
| 2012 | -3.11 Million USD | -46.07% |
| 2011 | -2.21 Million USD | -25.84% |
| 2010 | -1.76 Million USD | 32.1% |
| 2009 | -2.17 Million USD | 60.5% |
| 2008 | -6.27 Million USD | -156.9% |
| 2007 | -6.5 Million USD | 247.65% |
| 2006 | -7.67 Million USD | -15.62% |
| 2005 | -6.32 Million USD | 10.79% |
| 2004 | -7.44 Million USD | -71.16% |
| 2003 | -4.34 Million USD | -165.88% |
| 2002 | -1.63 Million USD | -273.64% |
| 2001 | -437.85 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -167 Thousand USD | 77.57% |
| 2024 Q2 | -283 Thousand USD | -88.89% |
| 2023 Q1 | -251 Thousand USD | 61.97% |
| 2023 FY | - USD | 65.86% |
| 2023 Q4 | -598 Thousand USD | -374.6% |
| 2023 Q3 | -126 Thousand USD | 66.75% |
| 2023 Q2 | -379 Thousand USD | -51.0% |
| 2022 Q2 | -1.06 Million USD | 42.88% |
| 2022 Q1 | -1.86 Million USD | -89.84% |
| 2022 FY | - USD | 1.63% |
| 2022 Q4 | -660 Thousand USD | 42.41% |
| 2022 Q3 | -1.14 Million USD | -7.4% |
| 2021 Q1 | -953 Thousand USD | -38.12% |
| 2021 Q2 | -1.05 Million USD | -11.12% |
| 2021 Q3 | -1.09 Million USD | -3.78% |
| 2021 Q4 | -984 Thousand USD | 10.46% |
| 2021 FY | - USD | 7.46% |
| 2020 Q3 | -1.12 Million USD | 28.68% |
| 2020 Q2 | -1.57 Million USD | -50.53% |
| 2020 FY | - USD | -40.19% |
| 2020 Q4 | -690 Thousand USD | 38.61% |
| 2020 Q1 | -1.04 Million USD | -238.83% |
| 2019 Q4 | -309 Thousand USD | 58.36% |
| 2019 Q3 | -742 Thousand USD | 13.01% |
| 2019 FY | - USD | -9.74% |
| 2019 Q2 | -853 Thousand USD | 32.36% |
| 2019 Q1 | -1.26 Million USD | -82.49% |
| 2018 Q1 | -1.1 Million USD | -204.7% |
| 2018 FY | - USD | -43.91% |
| 2018 Q4 | -691 Thousand USD | -45.17% |
| 2018 Q3 | -476 Thousand USD | 22.48% |
| 2018 Q2 | -614 Thousand USD | 44.33% |
| 2017 Q1 | -545 Thousand USD | -39.39% |
| 2017 FY | - USD | 23.92% |
| 2017 Q4 | -362 Thousand USD | -2.55% |
| 2017 Q3 | -353 Thousand USD | 44.76% |
| 2017 Q2 | -639 Thousand USD | -17.25% |
| 2016 Q3 | -576 Thousand USD | 24.21% |
| 2016 Q1 | -750 Thousand USD | 15.06% |
| 2016 Q2 | -760 Thousand USD | -1.33% |
| 2016 Q4 | -391 Thousand USD | 32.12% |
| 2016 FY | - USD | 17.92% |
| 2015 Q3 | -1.03 Million USD | -91.13% |
| 2015 Q2 | -541 Thousand USD | 28.15% |
| 2015 FY | - USD | -30.87% |
| 2015 Q4 | -883 Thousand USD | 14.6% |
| 2015 Q1 | -753 Thousand USD | -2.17% |
| 2014 Q4 | -737 Thousand USD | -41.19% |
| 2014 FY | - USD | 26.83% |
| 2014 Q3 | -522 Thousand USD | 10.15% |
| 2014 Q2 | -581 Thousand USD | 10.48% |
| 2014 Q1 | -649 Thousand USD | 28.6% |
| 2013 FY | - USD | -5.38% |
| 2013 Q3 | -553 Thousand USD | 2.98% |
| 2013 Q2 | -570 Thousand USD | 50.73% |
| 2013 Q4 | -909 Thousand USD | -64.38% |
| 2013 Q1 | -1.15 Million USD | -15.7% |
| 2012 Q1 | -552 Thousand USD | 11.4% |
| 2012 FY | - USD | -46.07% |
| 2012 Q3 | -801 Thousand USD | 3.14% |
| 2012 Q4 | -1 Million USD | -24.84% |
| 2012 Q2 | -827 Thousand USD | -49.82% |
| 2011 Q1 | -573 Thousand USD | -8.73% |
| 2011 Q2 | -569 Thousand USD | 0.7% |
| 2011 Q4 | -623 Thousand USD | -51.21% |
| 2011 Q3 | -412 Thousand USD | 27.59% |
| 2011 FY | - USD | -25.84% |
| 2010 Q1 | -489 Thousand USD | 8.26% |
| 2010 Q3 | -381 Thousand USD | -14.07% |
| 2010 Q4 | -527 Thousand USD | -38.32% |
| 2010 FY | - USD | 32.1% |
| 2010 Q2 | -334 Thousand USD | 31.7% |
| 2009 Q2 | -711 Thousand USD | -6.44% |
| 2009 FY | - USD | 60.5% |
| 2009 Q4 | -533 Thousand USD | 16.19% |
| 2009 Q1 | -668 Thousand USD | 12.68% |
| 2009 Q3 | -636 Thousand USD | 10.55% |
| 2008 Q4 | -765 Thousand USD | 40.97% |
| 2008 FY | - USD | -156.9% |
| 2008 Q1 | -1.72 Million USD | -110.5% |
| 2008 Q2 | -2.64 Million USD | -53.13% |
| 2008 Q3 | -1.29 Million USD | 51.02% |
| 2007 Q2 | -1.45 Million USD | -0.97% |
| 2007 Q4 | 16.46 Million USD | 851.26% |
| 2007 Q3 | -2.19 Million USD | -51.0% |
| 2007 FY | - USD | 247.65% |
| 2007 Q1 | -1.43 Million USD | 31.84% |
| 2006 FY | - USD | -15.62% |
| 2006 Q3 | -1.82 Million USD | 12.11% |
| 2006 Q4 | -2.1 Million USD | -15.35% |
| 2006 Q1 | -2.03 Million USD | -7.5% |
| 2006 Q2 | -2.07 Million USD | -1.98% |
| 2005 Q3 | -1.73 Million USD | 13.86% |
| 2005 Q4 | -1.89 Million USD | -9.38% |
| 2005 Q1 | -375.11 Thousand USD | 81.09% |
| 2005 Q2 | -2.01 Million USD | -436.63% |
| 2005 FY | - USD | 10.79% |
| 2004 Q4 | -1.98 Million USD | -8.24% |
| 2004 Q2 | -1.84 Million USD | 0.0% |
| 2004 FY | - USD | -71.16% |
| 2004 Q3 | -1.83 Million USD | 0.91% |
| 2003 FY | - USD | -165.88% |
| 2002 FY | - USD | -273.64% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 96.978% |
| AngioDynamics, Inc. | -14.29 Million USD | 90.351% |
| AtriCure, Inc. | -8.1 Million USD | 82.994% |
| Avinger, Inc. | -16.34 Million USD | 91.564% |
| Azenta, Inc. | 55.15 Million USD | 102.5% |
| BioLife Solutions, Inc. | -45.23 Million USD | 96.952% |
| The Cooper Companies, Inc. | 882.8 Million USD | 100.156% |
| Daxor Corporation | 329.74 Thousand USD | 518.208% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 89.551% |
| Femasys Inc. | -13.16 Million USD | 89.529% |
| GlucoTrack, Inc. | -7.09 Million USD | 80.553% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 114.526% |
| Hologic, Inc. | 1.29 Billion USD | 100.106% |
| ICU Medical, Inc. | 307.69 Million USD | 100.448% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.058% |
| KORU Medical Systems, Inc. | -9.39 Million USD | 85.329% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 102.815% |
| Innovative Eyewear, Inc. | -6.57 Million USD | 79.027% |
| Innovative Eyewear, Inc. | -6.57 Million USD | 79.027% |
| Masimo Corporation | 236.7 Million USD | 100.583% |
| Microbot Medical Inc. | -10.63 Million USD | 87.032% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 108.744% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 100.596% |
| NovoCure Limited | -175.86 Million USD | 99.216% |
| NEXGEL, Inc. | -2.73 Million USD | 49.487% |
| NEXGEL, Inc. | -2.73 Million USD | 49.487% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 98.406% |
| OraSure Technologies, Inc. | 76.15 Million USD | 101.811% |
| Pro-Dex, Inc. | 8.33 Million USD | 116.549% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 96.745% |
| Predictive Oncology Inc. | -13.18 Million USD | 89.539% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | 45.102% |
| QuidelOrtho Corporation | 545.6 Million USD | 100.253% |
| Repligen Corporation | 124.29 Million USD | 101.109% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -377.003% |
| STAAR Surgical Company | 33.22 Million USD | 104.151% |
| Sharps Technology, Inc. | -8.98 Million USD | 84.644% |
| Utah Medical Products, Inc. | 24.8 Million USD | 105.559% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 100.594% |
| Jin Medical International Ltd. | 3.44 Million USD | 140.054% |